Until now, most of the mutations reported on the LDLR site of 135–160 (Figure 6) are associated with a rare disease called Lipoprotein Glomerulopathy (LPG) (40) which results from an increased APOE serum level (41). Here, APOE is linked to lipoprotein glomerulopathy.